GLP-1 agonists and exercise: the future of lifestyle prioritization
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index; 112 of the 164 sources its claims cite were checked for support.
Abstract
Recent literature shows that GLP-1 receptor agonists are highly effective for weight loss and improving metabolic and cardiovascular health, often surpassing the results of lifestyle interventions alone, such as exercise and diet modification. However, long-term weight maintenance is more successful when exercise is included, as stopping GLP-1 therapy alone often leads to weight regain, while exercise helps preserve muscle mass and sustain weight loss. Combining GLP-1 receptor agonists with structured lifestyle changes, especially increased protein intake and strength training, can mitigate muscle loss and enhance overall outcomes. As a result, future obesity management is likely to prioritize integrated approaches that combine pharmacotherapy with lifestyle interventions, rather than replacing lifestyle changes with medication alone.
Overview
CoChat Summary
## TL;DR
This narrative mini-review argues that GLP-1 receptor agonists are highly effective for weight loss and cardiometabolic benefit, but exercise remains essential for preserving lean mass and sustaining weight loss. The paper’s central conclusion is that future obesity care should prioritize hybrid approaches combining pharmacotherapy with structured lifestyle intervention rather than medication alone.
## Key findings
- GLP-1RAs produce substantial weight loss, reported here as mean reductions of 7–9 kg over about a year, and can also improve BMI, waist circumference, blood pressure, lipid profiles, and cardiovascular outcomes.
- In a cited STEP-1 semaglutide analysis, lean mass decreased by ~9.7% while fat mass fell by ~19.3%; in SURMOUNT-1 tirzepatide, about ~25% of total weight lost was lean mass and ~75% was fat mass over 72 weeks.
- The paper states that GLP-1RAs generally yield greater short-term weight loss than exercise alone, but exercise is superior for maintaining lean mass and cardiorespiratory fitness.
- Recent randomized trials cited in the review suggest that combining GLP-1RAs with exercise can add benefits, including improved maintenance of weight loss after stopping pharmacotherapy and reductions in metabolic syndrome severity, abdominal obesity, oxidative stress, and inflammation.
## Methods
- This is a mini-review/narrative review, not an original empirical study.
- The authors report a targeted literature search in PubMed/MEDLINE and Scopus from January 2015 to August 2025 using terms related to GLP-1 receptor agonists, exercise, obesity, type 2 diabetes, and weight loss.
- Included evidence consisted of peer-reviewed randomized controlled trials, meta-analyses, and high-quality narrative/systematic reviews in English; preclinical/mechanistic studies were selectively included when they provided mechanistic insight.
## Limitations
- The paper states that the evidence base has no standardized exercise protocols, with wide variability in training type, frequency, intensity, and supervision.
- It also states that most trials have short follow-up periods, generally ≤6–12 months, and that heterogeneous body-composition measures and endpoints limit synthesis.
- Evident from the text: this review is narrative rather than systematic, so its conclusions depend on a targeted search and selective inclusion of studies, which may increase the risk of bias; the paper also explicitly notes a likely publication bias toward positive/synergistic findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
50 Valid · 3 Not valid · 9 Not checked · 10 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, long-term weight maintenance is more successful when exercise is included, as stopping GLP-1 therapy alone often leads to weight regain, while exercise helps preserve muscle mass and sustain weight loss.”
§ GLP-1 agonists and exercise: the future of lifestyle prioritization > Abstract
What the sources say
- Supportedcites [22] Wilding, 2022, Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes Obes Metab source
The Discussion reports that adults with overweight or obesity regained most of their weight loss within one year after semaglutide withdrawal. The Introduction also states that stopping weight-management medication is frequently followed by weight regain. The cited claim concerns withdrawal, not the sentence’s separate assertions about exercise. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The post-discontinuation phase remains the least investigated, although extension studies consistently show that weight regain occurs rapidly, with patients regaining up to two-thirds of the lost weight within one year after withdrawal (22).”
§ GLP-1 agonists and exercise: the future of lifestyle prioritization > Introduction
What the sources say
- Partly supportedcites [22] Wilding, 2022, Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes Obes Metab sourceExperimental — accuracy not yet measured
The Discussion reports that STEP 1 participants regained a mean of two-thirds of their prior weight loss during the year after semaglutide and structured lifestyle intervention were withdrawn. It describes regain in this extension as comparatively rapid, but this single study does not establish that extension studies consistently show equally rapid regain after GLP-1 therapy withdrawal generally. (LLM, conf=0.84)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, exercise may help maintain weight loss after cessation of pharmacotherapy (16, 17, 19, 21).”
§ GLP-1 agonists and exercise: the future of lifestyle prioritization > Introduction
What the sources say
- Partly supportedcites [16] Sandsdal, 2023, Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial, Cardiovasc Diabetol sourceExperimental — accuracy not yet measured
The Background (page unavailable) reports that exercise maintained diet-induced weight loss for one year. But the Study design (page unavailable) says participants began exercise or liraglutide after a low-calorie diet; it does not report weight maintenance after stopping pharmacotherapy. That timing is the unsupported part of the claim. (LLM, conf=0.86)
- Supportedcites [17] Locatelli, 2024, Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition, Diabetes Care source
The Conclusions propose that resistance training during incretin therapy may prevent rebound weight and fat gain after pharmacotherapy ceases. The paper presents this as a possibility requiring future study, consistent with the claim’s “may” wording. (LLM, conf=0.91)
- Supportedcites [19] Jensen, 2024, Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial, EClinicalMedicine source
The Abstract’s Interpretation says that adding supervised exercise to obesity pharmacotherapy seems to improve weight maintenance after treatment termination compared with pharmacotherapy alone. The Discussion likewise reports less weight and fat regain one year after combined exercise and liraglutide than after liraglutide alone. This supports the citing sentence’s hedged claim. (LLM, conf=0.94)
- Partly supportedcites [21] Zakaria, 2024, Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study, Metabol Open sourceExperimental — accuracy not yet measured
The Introduction (page not specified) describes physical activity as a cornerstone of weight management and behavioral change as important for sustaining weight loss. It does not show that exercise maintains weight loss specifically after pharmacotherapy stops; the withdrawal example reports weight regain after both semaglutide and lifestyle intervention ended. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
§ GLP-1 agonists and exercise: the future of lifestyle prioritization > Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Holst, 2024, GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management, Nat Metab source
- Partly supportedcites [4] Wang, 2023, GLP–1 receptor agonists for the treatment of obesity: Role as a promising approach, Front Endocrinol (Lausanne) sourceExperimental — accuracy not yet measured
The Future research outlook section says GLP-1R agonists reduce the risk of cardiovascular events, particularly relevant to people with diabetes. The passages on non-diabetic patients discuss weight loss, not cardiovascular events; our copy does not establish a reduction in major adverse cardiovascular events in both populations. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] Ansari, 2024, Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: A systematic review and meta-analysis, Endocrine Pract source
- Not checked — no full text of the sourcecites [6] Wong, 2025, Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: A systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials, Diabetes Care source
- Partly supportedcites [7] Popoviciu, 2023, Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials, Int J Mol Sci sourceExperimental — accuracy not yet measured
Section 4.5 reports that liraglutide reduced a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in participants with type 2 diabetes. The Introduction discusses weight loss in people without diabetes, but the reviewed passages do not establish a reduction in major adverse cardiovascular events in that population. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] Ussher, 2023, Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action, Nat Rev Cardiol source
- Partly supportedcites [9] Baggio, 2021, Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease, Mol Metab sourceExperimental — accuracy not yet measured
The 'Pitfalls and data limitations' section (page not provided) says long-acting GLP-1R agonists are cardioprotective in people with type 2 diabetes. It does not establish a reduction in major adverse cardiovascular events in non-diabetic populations; the MACE passage describes an outcome for a planned co-agonist trial, not a demonstrated reduction. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [10] Iqbal, 2022, Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta-analysis of randomized control trials, Obes Rev source
- Partly supportedcites [11] Davies, 2018, Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD), Diabetes Care sourceExperimental — accuracy not yet measured
The section on cardiovascular outcomes trials reports reduced major adverse cardiovascular events with liraglutide and semaglutide in trials of people with type 2 diabetes. It does not establish that GLP-1 receptor agonists reduce these events in non-diabetic populations; it also notes that cardiovascular benefit was not demonstrated for every agent studied. (LLM, conf=0.88)
- Partly supportedcites [12] Drucker, 2022, GLP-1 physiology informs the pharmacotherapy of obesity, Mol Metab sourceExperimental — accuracy not yet measured
The ‘GLP1RA and cardiovascular disease’ section reports reduced major adverse cardiovascular events in people with type 2 diabetes. It does not report such a reduction in people without diabetes: it describes preclinical findings in animals without diabetes and says the SELECT cardiovascular outcomes trial was still underway. Page numbers were not available in our copy. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
§ GLP-1 agonists and exercise: the future of lifestyle prioritization > Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Holst, 2024, GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management, Nat Metab source
- Partly supportedcites [4] Wang, 2023, GLP–1 receptor agonists for the treatment of obesity: Role as a promising approach, Front Endocrinol (Lausanne) sourceExperimental — accuracy not yet measured
The Experimental evidence section reports that, in the STEP 1 semaglutide trial, 69.1% of participants lost at least 10% of their weight and 50.5% lost at least 15%. It also reports weight loss with liraglutide, but gives those results in kilograms rather than showing that 10–15% loss is common with liraglutide or GLP-1RAs generally. The percentage range is therefore supported for semaglutide, not for the broader claim. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [5] Ansari, 2024, Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: A systematic review and meta-analysis, Endocrine Pract source
- Not checked — no full text of the sourcecites [6] Wong, 2025, Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: A systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials, Diabetes Care source
- Supportedcites [7] Popoviciu, 2023, Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials, Int J Mol Sci source
Section 5.4 (Average Weight Loss; page unavailable) reports mean weight loss of 14.9% and 15.2% in semaglutide trials. It also reports that some liraglutide recipients achieved at least 10% or 15% weight loss, although liraglutide's mean loss in the head-to-head trial was 6.4%. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [8] Ussher, 2023, Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action, Nat Rev Cardiol source
- Partly supportedcites [9] Baggio, 2021, Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease, Mol Metab sourceExperimental — accuracy not yet measured
The Summary (page not provided) reports greater than 15% weight loss with higher-dose semaglutide in investigational studies of people with obesity. This supports the possibility of substantial weight loss with a GLP-1RA, but does not establish that 10–15% or more is often achieved across GLP-1RAs, including liraglutide. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [10] Iqbal, 2022, Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta-analysis of randomized control trials, Obes Rev source
- Partly supportedcites [11] Davies, 2018, Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD), Diabetes Care sourceExperimental — accuracy not yet measured
In “Medications for Lowering Glucose” (page not available), the report says all GLP-1 receptor agonists reduce weight, including the class containing liraglutide and semaglutide. It gives a reduction of about 1.5–6.0 kg over roughly 30 weeks, not the claimed ‘often 10–15% or more’; that magnitude is unsupported by this source. (LLM, conf=0.90)
- Partly supportedcites [12] Drucker, 2022, GLP-1 physiology informs the pharmacotherapy of obesity, Mol Metab sourceExperimental — accuracy not yet measured
The section on semaglutide and weight loss in humans reports a mean loss of 16.9% in STEP 1, supporting substantial weight loss at or above the claimed range. The section on liraglutide and the treatment of obesity reports about 6% mean loss in several trials, so 10–15% or more is not representative of both named GLP-1RAs. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
21 more claims · 14 with their cited sources checked
Create a free account to see all 72 claims and every source verdict.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Bagherzadeh-Rahmani, 2024, Tirzepatide and exercise training in obesity, Clin Hemorheol Microcirc, 87, 10.3233/CH-242134”
Cited work 10.3233/ch-242134 · retracted 2025-11-23 · notice 10.1177/13860291251390410 · this paper published 2025-11-24
Citations
Cites
1 retracted
RETRACTED: Tirzepatide and exercise training in obesity
Bagherzadeh-Rahmani, B., Marzetti, E., Karami, E., Campbell, B. I., Fakourian, A., Haghighi, A. H., Mousavi, S. H., Heinrich, K. M., Brazzi, L., Jung, F., et al. (2024) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-242134 · Cited by 21
RetractedWorld Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657 · cited 2×
“A practical, three-step approach – adapted from current World Health Organization (56), American College of Sports Medicine (57), American Diabetes Association (58), and European Association for the Study of Obesity (59) guidelines – is recommended: (1) introduce regular movement gradually, targeting 150 minutes of mo…”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 7×
“Exercise and lifestyle interventions, while generally less potent for weight loss, provide unique and irreplaceable health bene fi ts – preserving skeletal muscle, improving cardiorespiratory fi tness, enhancing psychological well-being, and lowering chronic disease risk (11, 16, 18, 19).”
InfluentialPhysical activity/exercise and diabetes: A position statement of the American Diabetes Association
Colberg, S. R., Sigal, R. J., Yardley, J. E., Riddell, M. C., Dunstan, D. W., Dempsey, P. C., Horton, E. S., Castorino, K., & Tate, D. F. (2016) · Diabetes Care · doi:10.2337/dc16-1728 · Cited by 2,991
Exercise, physical activity, and self-determination theory: A systematic review
Teixeira, P. J., Carraça, E. V., Markland, D., Silva, M. N., & Ryan, R. M. (2012) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/1479-5868-9-78 · Cited by 2,963
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086 · cited 2×
“…three-step approach – adapted from current World Health Organization (56), American College of Sports Medicine (57), American Diabetes Association (58), and European Association for the Study of Obesity (59) guidelines – is recommended: (1) introduce regular movement gradually, targeting 150…”
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2413258 · Cited by 1,115
Research works printed but not linked: 1
- Ozemek, 2026, ACSM’s guidelines for exercise testing and prescription, 645 p
Cited by
Vandoni, M., Gatti, A., Rossi, V., Giuriato, M., Pellino, V. C., Zuccotti, G., & Calcaterra, V. (2026) · Obesity Reviews · doi:10.1111/obr.70189 · Cited by 3
Latest advances and controversies of exercise therapy in the management of type 2 diabetes
Hao, J., & Zhang, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1822069 · Cited by 1
“Second, exploring the synergistic effects of exercise and emerging therapies (such as GLP-1 receptor agonists) is crucial (24).”
Basso, A. L. F., Falcetti, E. M., Coelho, R. P., Maia, G. A., de Oliveira, L. R. B., Prates, F. F., & TREPICHE, S. D. (2026) · Research Society and Development · doi:10.33448/rsd-v15i6.51184
Kim, H., Chae, J. H., & Moon, H. Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02141-z
Ochani, S. (2026) · Asia Pacific Journal of Public Health · doi:10.1177/10105395261465730
Metadata
- Authors
- Codella, R., Senesi, P., & Luzi, L.
- Affiliations
- University of Milan (IT)
- MultiMedica (IT)
- Corresponding author
- Codella, Roberto
- Venue
- Frontiers in Clinical Diabetes and Healthcare
- Publisher
- Frontiers Media SA
- Published
- 2025-11-24
- Volume
- 6
- Pages
- 1720794-1720794
- ISSN
- 2673-6616 (ISSN-L)
- PMC
- PMC12683586
- OpenAlex
- W4417230669
- Cited by
- 16
- References
- 64
- Citations by year
- 2026: 16
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Clinical Diabetes and Healthcare (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministero della Salute
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, physical activity, obesity treatment, weight loss, weight maintenance, weight regain, muscle mass preservation, protein intake, resistance training, lifestyle intervention, pharmacotherapy, metabolic health, cardiovascular health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 agonists and exercise: the future of lifestyle prioritization. https://app.cochat.ai/papers/10.3389/fcdhc.2025.1720794
- The paper
- Codella, R., Senesi, P., & Luzi, L. (2025). GLP-1 agonists and exercise: the future of lifestyle prioritization. Frontiers in Clinical Diabetes and Healthcare. https://doi.org/10.3389/fcdhc.2025.1720794
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.